AYTU BIOPHARMA, INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
AYTU BIOPHARMA, INC (AYTU) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $26.00 thousand as of 2018-12-31, per its 10-Q filed 2019-05-14.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2019-05-14
- 2018-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $26.00K.
- 2018-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $94.00K.
- 2016-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $276.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2018-12-31 | $26.00K 10-Q · filed 2019-05-14 |
| 2018-06-30 | $94.00K 10-Q · filed 2019-05-14 |
| 2016-06-30 | $276.00K 10-K · filed 2018-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |